Install
Quality and Inspections
Quality and Inspections in Medicine: the news, the names and what changed.
- 17 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Quality and Inspections
Interactive Brokers Group (IBKR) Announces 71.4% Dividend Hike Amid Valuation Concerns
7+ hour, 6+ min ago (274+ words) On October 16, 2026, Interactive Brokers Group Inc IBKR declared a significant dividend increase of 71.4%, raising its quarterly payout from $0.0875 to $0.15 per share. This move comes alongside dividend boosts from peers such as Citizens Financial Group (CFG), Johnson & Johnson (JNJ), and Coca-Cola…...
Loar Holdings Inc. Stock 12‑Month Price Target Cut to $86.2, Implies 37% Upside
4+ hour, 13+ min ago (121+ words) TradingView Loar Holdings Inc. Stock 12‑Month Price Target Cut to $86.2, Implies 37% Upside - According to estimates from 5 analysts, Loar Holdings Inc. stock's average price target has fallen from $88.2 to $86.2, with forecasts ranging from $72 to $99 per share - Based on the Oct. 15 closing…...
Electra Therapeutics, Inc. (NASDAQ:ETRA) Stock Has Average Target Price of $34.00 According to Brokerages
8+ hour, 19+ min ago (98+ words) View Our Latest Research Report on ETRA Shares of NASDAQ:ETRA opened at $8.75 on Friday. Electra Therapeutics has a 52 week low of $8.50 and a 52 week high of $15.50. Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell…...
Orion Oyj: Relative Strength Chart - Stock Nasdaq Helsinki
4+ hour, 33+ min ago (36+ words) Compare Orion Oyj with the company of your choice via a Relative Strength chart. Real-time ORNBV price, Nasdaq Helsinki stock exchange Relative Strength Chart Orion Oyj All financial news and data tailored to specific country editions...
Sonida Senior Living, Inc. (NYSE:SNDA) Stock Now Rated "Hold" by Wall Street Analysts
12+ hour, 19+ min ago (117+ words) Check Out Our Latest Stock Report on SNDA Sonida Senior Living NYSE: SNDA is a senior living company that owns, operates and manages communities serving older adults across the United States. Its communities provide residential care and support designed to…...
Guggenheim maintains Buy rating on Tenet Healthcare, $307 price target
8+ hour, 2+ min ago (119+ words) Guggenheim maintained their Buy rating on Tenet Healthcare's stock with a price target of $307.00. The price target implies an upside of 11.6% from the Oct 15 close of $275.13. Strong Revenue and EBITDA Growth Expectations: Guggenheim forecasts Tenet Healthcare's 2026 revenue to reach $22.220 billion…...
Modulex Construction Technologies Share Price Near 52W Low
10+ hour, 7+ min ago (552+ words) Modulex Construction Technologies Ltd. (MODULEX) traded at Rs 13.21 versus the previous close of Rs 13.87, a fall of 4.76%. The stock opened at Rs 13.8, reached a high of Rs 13.8, touched a low of Rs 13.21. Modulex Construction Technologies Ltd. (MODULEX) fundamental metrics show…...
Ondas Holdings Inc. (NASDAQ:ONDS) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
12+ hour, 4+ min ago (915+ words) MarketBeat Ondas Holdings Inc. (NASDAQ:ONDS) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - Analyst sentiment is moderately bullish: Twelve firms rate Ondas Holdings an average “Moderate Buy,” with 10 buy ratings, one hold and one sell. The average 12-month price…...
Hagerty (NYSE:HGTY) Reaches New 1-Year High – Here’s What Happened
12+ hour, 52+ min ago (134+ words) Posted by Defense World Staff on Oct 16th, 2026 Hagerty, Inc. (NYSE:HGTY – Get Free Report)’s share price reached a new 52-week high during trading on Wednesday. The stock traded as high as $15.24 and last traded at $14.9870, with a volume of…...
Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target
9+ hour, 25+ min ago (116+ words) Needham reiterated their Buy rating on Neurocrine Biosciences's stock with a price target of $204.00. The price target implies an upside of 49.0% from the Oct 15 close of $136.95. Strong Portfolio of Approved Treatments: Neurocrine Biosciences has a robust lineup of FDA-approved treatments,…...